Target Price | $8.81 |
Price | $4.18 |
Potential |
110.83%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Aquestive Therapeutics, Inc. 2025 .
The average Aquestive Therapeutics, Inc. target price is $8.81.
This is
110.83%
register free of charge
$15.00
258.85%
register free of charge
$5.50
31.58%
register free of charge
|
|
A rating was issued by 8 analysts: 8 Analysts recommend Aquestive Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Aquestive Therapeutics, Inc. stock has an average upside potential 2025 of
110.83%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 50.58 | 58.08 |
6.08% | 14.83% | |
EBITDA Margin | -26.77% | -35.35% |
67.83% | 32.05% | |
Net Margin | -23.40% | -72.91% |
89.06% | 211.53% |
7 Analysts have issued a sales forecast Aquestive Therapeutics, Inc. 2024 . The average Aquestive Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Aquestive Therapeutics, Inc. EBITDA forecast 2024. The average Aquestive Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 Aquestive Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Aquestive Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.13 | -0.47 |
88.39% | 261.54% | |
P/E | negative | |
EV/Sales | 7.02 |
2 Analysts have issued a Aquestive Therapeutics, Inc. forecast for earnings per share. The average Aquestive Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Aquestive Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Aquestive Therapeutics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.